AIMC Topic: Antineoplastic Agents, Immunological

Clear Filters Showing 11 to 17 of 17 articles

Prediction of methionine oxidation risk in monoclonal antibodies using a machine learning method.

mAbs
Monoclonal antibodies (mAbs) have become a major class of protein therapeutics that target a spectrum of diseases ranging from cancers to infectious diseases. Similar to any protein molecule, mAbs are susceptible to chemical modifications during the ...

Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer.

Scientific reports
Tissue biomarker scoring by pathologists is central to defining the appropriate therapy for patients with cancer. Yet, inter-pathologist variability in the interpretation of ambiguous cases can affect diagnostic accuracy. Modern artificial intelligen...

Predicting the efficacy of bevacizumab on peritumoral edema based on imaging features and machine learning.

Scientific reports
This study proposes a novel approach to predict the efficacy of bevacizumab (BEV) in treating peritumoral edema in metastatic brain tumor patients by integrating advanced machine learning (ML) techniques with comprehensive imaging and clinical data. ...

[ARTIFICIAL INTELLIGENCE-ASSISTED LITERATURE REVIEW: A CASE STUDY IN FUMARATE HYDRATASE-DEFICIENT RENAL CELL CARCINOMA].

Harefuah
Fumarate hydratase-deficient renal cell carcinoma (FHdRCC) is a rare and aggressive form of kidney cancer that presents significant therapeutic challenges. Due to its rarity, treatment decisions often rely on comprehensive literature reviews to ident...

[CLINICAL EVALUATION OF THERAPEUTIC EFFECT PREDICTORS IN PEMBROLIZUMAB FOR ADVANCED UROTHELIAL CANCER].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology
(Purpose) We performed a clinical retrospective study on the evaluation of pembrolizumab treatment results for advanced urothelial cancer in our hospital. (Materials and Methods) Twenty-seven patients diagnosed with advanced or metastatic urothelial ...

Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies.

mAbs
Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs) are tremendous, the design and discovery of new candidates remain a time and cost-intensive endeavor. In this regard, progress in the generation of data describi...